Researchers from the University of Michigan examined vaccination against human papillomavirus (HPV) in young adults versus adolescents for an 8-year period, from 2010 to 2018. Regardless of what age they were at first dose, more survey respondents opted for vaccination as the years passed. Still, compared with adolescents—68% of whom received one or more HPV doses by 2018—overall takeup among young adults was low.

On April 30, FDA announced the approval of a higher dosage of naloxone hydrochloride nasal spray (Kloxxado—Hikma Pharmaceuticals) to treat opioid overdose. The newly approved product delivers 8 mg of naloxone into the nasal cavity, compared with previously approved 2- and 4-mg naloxone nasal spray products.

Annual cases of sexually transmitted diseases (STDs) in the United States continued to increase in 2019, hitting an all-time high for the sixth consecutive year, according to new CDC data.